Benefits of testosterone therapy for patients with hypogonadism or type 2 diabetes
“Most importantly, the improvement that they were able to get during the first couple of years is sustained, whereas what we expect in untreated men [is that] their erectile function…keeps on deteriorating,” says Karim Sultan Haider, MD.
In this video, Karim Sultan Haider, MD, discusses the background and findings of the study, “Long-term Testosterone Therapy Improves Erectile Function and Reduces Mortality in Men with Hypogonadism and Type 2 Diabetes – Updated Results from a Registry Study,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Sultan Haider is an andrology and urology resident at Gesundheit Nord, Bremen, Germany.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
